Gepotidacin, an oral type II topoisomerase inhibitor marketed as Blujepa for uncomplicated urinary tract infections following its March 2025 approval, is under further regulatory review for use against gonorrhea. The compound’s distinct dual‑target binding mode distinguishes it from fluoroquinolones and offers a potential route to treat resistant Neisseria gonorrhoeae while sparing gut microbiota. Sponsors emphasize gepotidacin’s mechanism could address fluoroquinolone resistance, but final indications and labeling for gonorrhea will depend on ongoing FDA review outcomes and additional clinical data.